Table 1.
Demographic and baseline characteristics of patients who received ≥1 dose of deferasirox during the extension study
| Paediatric patients (n = 162) | Adult patients (n = 69) | |
|---|---|---|
| Mean age ± SD, yr | 9.5 ± 3.6 | 21.2 ± 5.8 |
| Female/male, n | 80:82 | 34:35 |
| Race (Caucasian/Oriental/other), n | 59:82:21 | 11:38:20 |
| History of hepatitis B only, n (%) | 0 (0) | 0 (0) |
| History of hepatitis C only, n (%) | 41 (25.3) | 26 (37.7) |
| History of hepatitis B and C, n (%) | 3 (1.9) | 1 (1.4) |
| Splenectomy, n (%) | 46 (28.4) | 47 (68.1) |
| Previous chelation therapy, n (%) | ||
| Deferoxamine (DFO) monotherapy | 145 (89.5) | 39 (56.5) |
| Deferiprone monotherapy | 1 (0.6) | 3 (4.3) |
| DFO + deferiprone1 | 16 (9.9) | 27 (39.1) |
| Median duration of previous chelation therapy (range), yr2 | 5.2 (0.1–13.2) | 12.2 (3.1–21.0) |
| Mean transfusion history duration ± SD, yr | 8.6 ± 3.7 | 18.9 ± 5.6 |
| Mean number of transfusion sessions in the year prior to study entry ± SD | 15.5 ± 4.4 | 14.3 ± 3.8 |
| Mean amount transfused in the year prior to study entry ± SD, mL/kg/d | 0.50 ± 0.18 | 0.39 ± 0.17 |
SD, standard deviation.
1
Patients had received prior chelation with DFO and deferiprone, although these may not have been given in combination.
2
Paediatric patients n = 121 and adult patients n = 49.